OBJECTIVE: We attempted to determine the decision rules psychiatrists use in the choice of antipsychotic drugs for inpatients with schizophrenia. METHODS: Interviews were conducted with 50 hospital psychiatrists in Southern Germany. Each physician was interviewed with respect to the reasons for his antipsychotic drug choice in the cases of three patients with a diagnosis of schizophrenia. Interviews were audiotaped and subsequently analyzed using a standardized coding scheme. RESULTS: The clinical decision rules identified are highly complex, with a mean of eight categories cited per patient. Categories named included the patient's past treatment response, side effects, intended route of administration and co-morbidities. Moreover, psychiatrists strongly take the patient's target symptoms and the assumed efficacy of certain compounds into account in their choice of medication. CONCLUSION: Psychiatrists' explanations for their antipsychotic drug choice seem for the most part reasonable and overlap substantially with drug-choice algorithms of clinical guidelines. However, psychiatrists additionally use indicators that--in their view--might predict treatment response. For these indicators, which are derived from personal experience, it is still unclear whether they are valid and simply have not yet been proven in clinical trials or whether they merely represent unfounded assumptions on the part of the doctors.
OBJECTIVE: We attempted to determine the decision rules psychiatrists use in the choice of antipsychotic drugs for inpatients with schizophrenia. METHODS: Interviews were conducted with 50 hospital psychiatrists in Southern Germany. Each physician was interviewed with respect to the reasons for his antipsychotic drug choice in the cases of three patients with a diagnosis of schizophrenia. Interviews were audiotaped and subsequently analyzed using a standardized coding scheme. RESULTS: The clinical decision rules identified are highly complex, with a mean of eight categories cited per patient. Categories named included the patient's past treatment response, side effects, intended route of administration and co-morbidities. Moreover, psychiatrists strongly take the patient's target symptoms and the assumed efficacy of certain compounds into account in their choice of medication. CONCLUSION: Psychiatrists' explanations for their antipsychotic drug choice seem for the most part reasonable and overlap substantially with drug-choice algorithms of clinical guidelines. However, psychiatrists additionally use indicators that--in their view--might predict treatment response. For these indicators, which are derived from personal experience, it is still unclear whether they are valid and simply have not yet been proven in clinical trials or whether they merely represent unfounded assumptions on the part of the doctors.
Authors: Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112
Authors: Xinhua S Ren; Lewis E Kazis; Austin F Lee; Yu-Hui Huang; Alaa Hamed; Francesca Cunningham; Lawrence Herz; Donald R Miller Journal: Schizophr Res Date: 2005-09-15 Impact factor: 4.939
Authors: Johannes Hamann; Bernadette Langer; Stefan Leucht; Raymonde Busch; Werner Kissling Journal: Am J Psychiatry Date: 2004-07 Impact factor: 18.112
Authors: Mark Zimmerman; Michael Posternak; Michael Friedman; Naureen Attiullah; Scott Baymiller; Robert Boland; Stacie Berlowitz; Shahzad Rahman; Kirsten Uy; Steve Singer Journal: Am J Psychiatry Date: 2004-07 Impact factor: 18.112
Authors: Herbert Y Meltzer; Larry Alphs; Alan I Green; A Carlo Altamura; Ravi Anand; Alberto Bertoldi; Marc Bourgeois; Guy Chouinard; M Zahur Islam; John Kane; Ranga Krishnan; J P Lindenmayer; Steven Potkin Journal: Arch Gen Psychiatry Date: 2003-01
Authors: Mary F Brunette; Robert O Cotes; Alexander de Nesnera; Gregory McHugo; Nino Dzebisashvili; Haiyi Xie; Stephen J Bartels Journal: Psychiatr Serv Date: 2018-06-08 Impact factor: 3.084